Who is sponsoring NCT05829421?

NCT05829421 is sponsored by Emma Ghaziani.

What drugs are being tested in NCT05829421?

Interventions in NCT05829421: Impairment-specific occupational therapy (OT) intervention.

What condition does NCT05829421 study?

NCT05829421 studies Cognitive Impairment, Stroke.

Is NCT05829421 still recruiting?

NCT05829421 is currently completed. Last updated 5 December 2025.

Last reviewed 2025-12-05 · How we verify

NCT05829421: NIOTI-stroke

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Addressing Problems in Managing Daily Tasks Due to Poststroke Cognitive Impairments

Completed NA Last updated 5 December 2025

What this trial tests

NA trial testing Impairment-specific occupational therapy (OT) intervention in Cognitive Impairment in 8 participants. Completed in 1 October 2025.

Timeline

25 May 2023

Primary endpoint
29 March 2024

1 October 2025

Quick facts

Lead sponsor	Emma Ghaziani
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	25 May 2023
Primary completion	29 March 2024
Estimated completion	1 October 2025
Sites	4 locations across Denmark

Drugs / interventions tested

Impairment-specific occupational therapy (OT) intervention

Conditions studied

Cognitive Impairment — all drugs for Cognitive Impairment →
Stroke — all drugs for Stroke →

Sponsor

Emma Ghaziani

Who can join

18 and older, any sex, with Cognitive Impairment or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate feasibility aspects of an intervention targeting problems in managing daily tasks due to mild-to-moderate poststroke cognitive impairments. We will specifically address uncertainties related to intervention content and delivery, and trial design and conduct.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cognitive Impairment

Currently open trials in the same condition.

NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05829421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emma Ghaziani
Last refreshed: 5 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05829421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing